Martínez Vicente, L.Gajate García, V.Gutiérrez Gutiérrez, GerardoGuerrero Peral, Á. L.Horga Hernández, A.Guerrero Sola, AntonioÁlvarez Troncoso, JRestrepo Córdoba, M. AGoirigolzarri Artaza, JMartín Albarrán, SEt. al.2026-02-202026-02-202025Martínez-Vicente, L., Gajate-García, V., Gutiérrez-Gutiérrez, G., Guerrero-Peral, Á. L., Horga, A., Guerrero-Sola, A., Álvarez-Troncoso, J., Restrepo-Córdoba, M. A., Goirigolzarri-Artaza, J., Martín-Albarrán, S., Valverde-Megías, A., González-López, E., García-Pavía, P., Matías-Guiu, J., & Galán-Dávila, L. (2025). Redefining therapeutics in vATTR: Evaluation of response predictors to tafamidis and patisiran treatment in a non-endemic area. A proposal for a novel individualised therapeutic approach. Neurología, 501920. https://doi.org/10.1016/j.nrl.2025.5019200213-48531578-1968https://hdl.handle.net/11268/16861Hereditary transthyretin amyloidosis (vATTR) is a progressive genetic disorder with several approved treatments. This study aims to investigate treatment responses to tafamidis and patisiran in vATTR patients to identify predictive response factors. Retrospective analysis on vATTR patients treated with tafamidis or patisiran from October 2012 to September 2022. Treatment responses were assessed as “good,” “partial,” or “non-response.” It was analysed pre-treatment clinical and laboratory data to identify predictors of treatment response.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AlgoritmosAmiloidosisEnfermedades metabólicasjournal article10.1016/j.nrl.2025.501920open accessAlgoritmoTratamiento médicoInvestigación médicaGoal 3: Ensure healthy lives and promote well-being for all at all ages